Medscape
MADRID — Amycretin, a dual pathway, oral weight loss drug, led to up to 13% body weight loss in participants with overweight or obesity according to phase 1, first-in-human study data presented at the European Association for the Study of Diabetes (EASD) 2024 annual meeting. Body weight loss was “remarkable for an orally delivered biologic,” …
Read More
‘Remarkable’ Weight Loss With Novel Oral Combo in Phase 1
Tyisha Lupo
19:56
MADRID — Amycretin, a dual pathway, oral weight loss drug, led to up to 13% body weight loss in participants with overweight or obesity according to phase 1, first-in-human study data presented at the European Association for the Study of Diabetes (EASD) 2024 annual meeting. Body weight loss was “remarkable for an orally delivered biologic,”
